Issue 6/2012

  • Obama’s new biobased economy

    In this issue:

    • Cover Story: Obama’s new biobased economy - The bioeconomy begins to go truly global
    • GSK absorbs Cellzome; German biotech sector expanding
    • Abbott buys kidney treatment from Action Pharma
    • DSM enters biomedicine with takeover of Kensey Nash
    • SPECIAL: BiobasedWorld at Achema – The guide to the trade fair
    • Zeltia pockets Yondelis milestone from Johnson & Johnson
    • Selvita stuffs its war-chest with shares, grants and awards
    • Pattern of DNA methylation determines genome stability

Volume 2015

Volume 2014

Volume 2013

Volume 2012

© 2007-2015 BIOCOM

http://www.european-biotechnology-news.com/magazine/ebsin/2012/6/pos/1.html?sort=asc&cHash=2aa63e7a3c47f54d547eeaaa494e591b

Kurszettel

Alle Kurse

TOP

  • IMMUNICUM AB (S)33.00 SEK32.00%
  • ZEALAND PHARMA (DK)151.00 DKK4.86%
  • CYTOS (CH)0.46 CHF4.55%

FLOP

  • OREXO (S)53.25 SEK-28.76%
  • THERAMETRICS (CH)0.06 CHF-14.29%
  • ZELTIA (E)3.69 EUR-8.44%

TOP

  • CHRONTECH PHARMA (S)0.02 SEK100.0%
  • DBV TECHNOLOGIES (F)80.79 EUR53.2%
  • BIOTIE THERAPEUTICS (FI)0.22 EUR37.5%

FLOP

  • BIOTEST (D)26.60 EUR-61.7%
  • BIOTECH PHARMACON (N)9.30 NOK-46.9%
  • EVOCUTIS (UK)0.16 GBP-27.3%

TOP

  • ADOCIA (F)89.23 EUR535.1%
  • DBV TECHNOLOGIES (F)80.79 EUR324.1%
  • FORMYCON (D)28.54 EUR319.1%

FLOP

  • CHRONTECH PHARMA (S)0.02 SEK-77.8%
  • NEUROVIVE PHARMACEUTICAL AB (S)22.50 SEK-72.0%
  • NEOVACS (F)1.04 EUR-69.7%

No liability assumed, Date: 04.08.2015